TRPX - Therapix Biosciences Ltd.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 511.34M
Enterprise Value 39.93M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)48.49
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6-1.12

Trading Information

Stock Price History

Beta (3Y Monthly) 0.82
52-Week Change 3-53.70%
S&P500 52-Week Change 39.71%
52 Week High 39.3000
52 Week Low 32.0400
50-Day Moving Average 32.6316
200-Day Moving Average 32.7554

Share Statistics

Avg Vol (3 month) 3113.58k
Avg Vol (10 day) 3148.3k
Shares Outstanding 53.51M
Float 4.02M
% Held by Insiders 12.08%
% Held by Institutions 10.00%
Shares Short (Sep. 30, 2019) 4142.22k
Short Ratio (Sep. 30, 2019) 42.4
Short % of Float (Sep. 30, 2019) 4N/A
Short % of Shares Outstanding (Sep. 30, 2019) 43.22%
Shares Short (prior month Aug. 30, 2019) 4186.34k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 31, 2018
Most Recent Quarter (mrq)Mar. 31, 2019


Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)N/A
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
Net Income Avi to Common (ttm)-8.61M
Diluted EPS (ttm)-2.5690
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)1.49M
Total Cash Per Share (mrq)0.36
Total Debt (mrq)1.15M
Total Debt/Equity (mrq)1,489.61
Current Ratio (mrq)N/A
Book Value Per Share (mrq)0.05

Cash Flow Statement

Operating Cash Flow (ttm)N/A
Levered Free Cash Flow (ttm)N/A